Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Speculative Buy and lowers the price target from $18 to $13.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.